Giredestrant cut the risk of disease progression or death by 44% compared with standard endocrine therapy plus everolimus in patients with ER-positive advanced breast cancer, according to full phase III evERA results published October 1 in The New England Journal of Medicine. That hazard ratio, from the intention-to-treat population, is the clearest evidence yet that an oral SERD paired with an mTOR inhibitor can outperform the current backbone regimen rather than merely match it.
The comparison matters because everolimus in combination with an aromatase inhibitor has been a standard option since its 2012 FDA approval, and adding the injectable SERD fulvestrant to that backbone has been the incremental move for patients who progress on prior hormonal therapy. Giredestrant is oral, which removes the intramuscular injection burden, but the clinical argument in evERA rests on the PFS separation, not the route of administration.
Roche’s earlier phase II coopERA study showed giredestrant beating standard of care on anti-proliferative activity in early-stage disease, so a phase III signal was anticipated. What evERA adds is the magnitude: a 44% risk reduction in a large, randomized trial is a harder number to dismiss during regulatory review than a biomarker endpoint in a neoadjuvant setting. Publication in NEJM, rather than a conference abstract, also puts the full dataset in front of regulators and payers simultaneously.
The practical question now is whether overall survival data will follow the PFS curve. Regulators increasingly accept PFS as a primary endpoint in ER-positive metastatic breast cancer, but payer committees in several markets want OS or at minimum a patient-reported outcomes signal before committing to a price that reflects a step-change over existing therapy. The OS readout from evERA will be the number that determines whether giredestrant earns a label position ahead of, rather than alongside, the current standard.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
